Table 7.
Ongoing clinical trials
| Trial size | Primary endpoint | Secondary endpoint | |
|---|---|---|---|
| Italian Platelet Technology Assessment Study (IPTAS), Italy | 840 | Number of patients with ≥ grade 2 bleeding | CCI |
| platelet and RBC transfusions | |||
| transfusion interval | |||
| allo-antibody formation from Luminex assay | |||
| Pathogen Reduction – Extended Storage Study (PRESS), Denmark | 40 | TEG measurements and correlation with CCI | adverse events |
| bleeding | |||
| Pathogen Reduction Evaluation and Predictive Analytical Rating Score (PREPARES), the Netherlands | 618 | number of patients with ≥ grade 2 bleeding | CCI |
| platelet and RBC transfusions | |||
| transfusion interval | |||
| allo-antibody formation from Luminex assay | |||